Welcome to our dedicated page for Inogen news (Ticker: INGN), a resource for investors and traders seeking the latest updates and insights on Inogen stock.
Inogen reports recurring developments as a respiratory medical technology company serving homecare patients with chronic respiratory conditions. Its updates focus on financial results and outlook, portable oxygen concentrators, Simeox airway clearance, stationary oxygen concentrators, and Aurora CPAP masks for obstructive sleep apnea.
Company news also covers product introductions, clinical evidence and reimbursement work, international market activity, commercial partnerships, leadership and board changes, inducement equity awards, share repurchase actions, and investor conference participation.
Inogen (Nasdaq: INGN) reported Q1 2026 revenue of $85.1M, up 3.4% year-over-year, and reiterated full-year 2026 revenue guidance of $366M–$373M. GAAP net loss was $8.3M; adjusted net loss was $4.0M; adjusted EBITDA was -$1.4M. Cash and equivalents totaled $111.5M with no debt.
The company authorized a $30.0M share repurchase program, repurchased 298,100 shares for $1.9M, launched CPAP masks in the U.S., expanded internationally, and noted clinical and reimbursement trial progress.
Inogen (Nasdaq: INGN) will report first quarter 2026 financial results after market close on May 7, 2026 and host a conference call the same day at 2:00 p.m. PT / 5:00 p.m. ET.
Live audio webcast, archived recording for six months, and a replay available through May 14, 2026 are accessible via the Inogen Investor Relations website. Dial-in and conference ID details are provided for live and replay access.
Inogen (Nasdaq: INGN) appointed Vafa Jamali as an independent director, effective at the Company’s 2026 Annual Meeting or June 15 if earlier. Mr. Jamali brings medical device leadership, including prior roles leading a $3 billion division and overseeing 10,000 team members.
The company entered a cooperation agreement with investor Kent Lake that includes customary standstill and voting provisions; the agreement will be filed on Form 8-K. Evercore, Covington & Burling, and Joele Frank advise the company.
Inogen (Nasdaq: INGN) said CEO Kevin Smith will appear in a virtual fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2026 at 10:15 a.m. ET. A live audio webcast and archived recording will be available on Inogen's investor relations website.
The company also stated it uses its investor relations website as a channel for disclosing material non-public information and to comply with Regulation FD.
Inogen (Nasdaq: INGN) announced inducement equity awards approved under Nasdaq Listing Rule 5635(c)(4) for two new executives joining the company. Jason Richardson will receive 200,000 RSUs (100,000 time-based; 100,000 performance-based, up to 150,000 PSUs if goals are exceeded). Dominic Hulton will receive $200,000 in time-based RSUs, with his start expected on April 1, 2026. Vesting for both grants is generally one-third annually over three years for the time-based RSUs; PSUs vest upon achievement of specified performance goals. Awards are outside the company’s 2023 equity plan but follow similar terms.
Inogen (Nasdaq: INGN) announced leadership changes to support its next growth phase, naming Jason Richardson as CFO effective April 6, 2026, Dominic Hulton as Chief Marketing Officer effective April 1, 2026, and Corey Moritz as VP, U.S. B2B Sales (joined March 9, 2026).
The company said Michael Bourque will step down as CFO and remain as advisor through June 30, 2026. Inogen also reaffirmed its Q1 and full year 2026 financial outlook provided on February 24, 2026.
Inogen (Nasdaq: INGN) announced that CEO Kevin Smith will appear in a virtual fireside chat at the KeyBanc Virtual Life Sciences & MedTech Investor Forum on March 17, 2026 at 3:00 PM ET. A live audio webcast and archived recording will be available via the company investor relations website.
Inogen said it uses its investor relations site for disclosing material non-public information and to comply with Regulation FD.
Inogen (NASDAQ: INGN) reported full year 2025 results and 2026 outlook. Full year revenue was $348.7M, roughly 4% growth, with GAAP net loss of $22.7M and positive adjusted EBITDA of $2.7M. Cash and marketable securities were $120.9M with no debt and a $30M share repurchase authorization.
The company cited international POC sales strength and operational cost reductions, expects Q1 2026 revenue roughly in line with Q1 2025, and full year 2026 revenue guidance of $366M–$373M.
Inogen (Nasdaq: INGN) announced a $30 million share repurchase program authorized by its Board of Directors on February 24, 2026. The program will be financed through cash flow and existing cash reserves and may be suspended or terminated at any time.
The authorization expires on December 31, 2027, or once the $30 million cap is used, whichever occurs first. The company said the buyback reflects confidence in its strategy, progress toward profitability, a debt-free balance sheet, and provides flexibility to support innovation and portfolio expansion.
Inogen (Nasdaq: INGN) announced preliminary, unaudited revenue for Q4 2025 of approximately $82 million (≈2% YoY) and full‑year 2025 revenue of approximately $349 million (≈4% YoY). The company expects to achieve positive Adjusted EBITDA for 2025 and cited strong B2B channel performance offset by timing shifts of several large customer orders into H1 2026. Management highlighted product launches during 2025 including the Voxi 5 stationary oxygen concentrator and Aurora Masks for OSA patients in the U.S. Inogen will release full results and 2026 guidance on a February 24, 2026 earnings call.